Blood-Borne Amyloid-beta Dimer Correlates with Clinical Markers of Alzheimer's Disease
Victor L Villemagne, Keyla A Perez, Kerryn E Pike, W Mei Kok, Christopher C Rowe, Anthony R White, Pierrick Bourgeat, Olivier Salvado, Justin Bedo, Craig A Hutton, Noel G Faux, Colin L Masters, Kevin J Barnham
JOURNAL OF NEUROSCIENCE | SOC NEUROSCIENCE | Published : 2010
Alzheimer's disease (AD) is the most common age-related dementia. Unfortunately due to a lack of validated biomarkers definitive diagnosis relies on the histological demonstration of amyloid-beta (Abeta) plaques and tau neurofibrillary tangles. Abeta processing is implicated in AD progression and many therapeutic strategies target various aspects of this biology. While Abeta deposition is the most prominent feature of AD, oligomeric forms of Abeta have been implicated as the toxic species inducing the neuronal dysfunction. Currently there are no methods allowing routine monitoring of levels of such species in living populations. We have used surface enhanced laser desorption ionization time ..View full abstract
This work was funded by National Health and Medical Research Council of Australia (NHMRC).